Compare iShares China Large-Cap ETF (FXI) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares China Large-Cap ETF vs Mesoblast Limited — how do they compare? iShares China Large-Cap ETF trades at $34.24 (market cap $3.86B), while Mesoblast Limited trades at $14.33 (market cap $1.75B). The key difference: iShares China Large-Cap ETF is far larger — about 2.2× Mesoblast Limited's market cap, and iShares China Large-Cap ETF is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares China Large-Cap ETF for 149 Days and Mesoblast Limited for 14 Days on average.
| FXI | MESO | |
|---|---|---|
Market Cap | $3.86B | $1.75B |
Volume | 16,323,837 | 239,027 |
52-Week High | $41.08 | $20.96 |
52-Week Low | $31.59 | $13.19 |
Typical Hold Time | 149 Days | 14 Days |
Sector | — | Health |
Enterprise Value | — | $1.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FXI (iShares China Large-Cap ETF) trades at $34.30, up 2.63% on the day, but technical indicators signal a bearish trend with 17 sell signals versus 1 buy. The ETF faces headwinds from China's economic challenges and geopolitical tensions, though some analysts highlight its attractive valuation at half the S&P 500's P/E ratio. Recent news focuses on U.S.-China relations and export dynamics.
The outlook remains cautious due to China's industrial overcapacity and weak domestic consumption. While valuation appears compelling, political risks and technical weakness suggest limited near-term upside. Investors should weigh the discount against ongoing macroeconomic pressures in China.
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares China Large-Cap ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index designed to measure the performance of the largest companies in the Chinese equity market that trade on the Stock Exchange of Hong Kong and are available to international investors. The fund is non-diversified.
Read more on FXI →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
